Cited in boardrooms, legal proceedings & government briefings since 2017
Medical cannabis is legal in Switzerland and adult-use is pilot. Below: a free market overview, with the full sizing, regulation and trade data available from PP.
Medical cannabis sales and registered patients in Switzerland, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the Switzerland data pack.
Medical sales, EUR
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| Medical sales | €4.5m | €6m | €7.7m | |||
| Patients | 4,886 | 5,735 | 6,587 |
Forecasts to 2030 — sales, patients and the full Switzerland series — are in the Switzerland data pack, or scoped to your question in a bespoke brief.
See the data pack Request a briefSource: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)
How Switzerland’s framework got here, and what moves next.
Exemption-based patient access
Patients can access medical cannabis with a specific exemption from the federal health regulator.
Prescribing without exemption
Medical cannabis is reclassified from prohibited (Schedule D) to controlled (Schedule A) narcotic; doctors can prescribe directly.
First adult-use pilot launches
Study participants can legally purchase cannabis; seven pilot projects now operate with no reported public-health disruptions.
Legalisation drafting approved
A legislative committee gives preliminary approval to draft a plan to legalise adult-use cannabis.
Potential adult-use legalisation
The drafting timetable makes a regulated Swiss adult-use market possible as early as 2026.
From International Cannabis Weekly, our free global briefing.
Newsweed · №466 · 11 Sept 2026 · Medical
Business of Cannabis · №457 · 10 Jul 2026 · Adult-use
Business of Cannabis · №456 · 3 Jul 2026 · Adult-use
Hanf Magazin · №455 · 26 Jun 2026 · Business & Investment
sanitygroup.com · №454 · 19 Jun 2026 · Business & Investment
Proactive · №454 · 19 Jun 2026 · Business & Investment
Medical cannabis treatment has been legal in Switzerland since 2011, when a regulatory change allowed patients to access medical cannabis after obtaining a specific exemption to do so from the country’s health regulator. In 2022, this system was updated, and an exemption is no longer required for a doctor to prescribe medical cannabis to a patient.
Despite the rule change in 2022, patient numbers in the country have not grown significantly in recent years. This is due to a number of factors, but chiefly the bureaucracy associated with treating patients, in particular with seeking reimbursement for treatment, which is granted on a case-by-case basis.
The Swiss medical market has always been supplied primarily by a small number of domestic producers, as well as imports of dronabinol from Germany. There are now more imports coming into the country from other countries, and domestic producers are trying to scale up to export to the German and UK markets. Overall levels of activity on both fronts are still relatively small.
Unlike most other medical cannabis markets, the Swiss market is dominated by extracts. There is currently an approximate 80/20 split in favour of extract in the proportion of products used in patient treatment. Click here for premium data packages, including patient population forecasts.
In the full Switzerland market data
Sizing, forecasts, pricing, trade flows and licensed operators — verified by PP’s analysts. Available as a data pack.
